Identifiants & Marche
Ticker
GMTX
ISIN
US36870G1058
CIK
0001816736
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
US
Siege
N/A
Fondee
N/A
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.